Low Wang has patients who are trying the new weight loss drugs, but many are experiencing shortages, especially for the higher doses, like the 2.4 mg
Omics technologies, including genomics, metabolomics, and proteomics, enable scientists to explore genetic signatures that may predispose individuals to NAION or influence their response to medications
Third, supply chain dynamics are shifting
Even if theyre smiling and saying I feel great, still ask: Some of my patients notice subtle mood shifts while adjusting to these medicationsanything like that for you? I feel off is enough reason to pause and reassess
Some members have noticed major improvements: Others lost weight or improved their diabetes control but didnt see a change in HS: GLP-1s are relatively new, so healthcare professionals are still learning how they affect HS
Glutathione S-Transferases as Regulators of Kinase Pathways and Anticancer Drug Targets